-
Electrical storm and refractory heart failure necessitating left ventricular assist device in ischaemic cardiomyopathy with apical aneurysm. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-16 Yuanhong Li,Yuhong Wang,ChengXin Zhang
-
Circadian patterns of atrial fibrillation and disease progression assessed by implanted loop recorders Eur. Heart J. (IF 37.6) Pub Date : 2025-06-16 Daniel Camillo Spona, Ketil Jørgen Haugan, Claus Graff, Søren Højberg, Derk Krieger, Axel Brandes, Lars Køber, Morten S Olesen, Jesper Hastrup Svendsen, Søren Zöga Diederichsen
Background and Aims The heterogeneity of atrial fibrillation (AF) necessitates better phenotyping. This study aimed to explore circadian patterns of AF and their impact on AF characteristics and progression. Methods Post hoc analysis of the LOOP study randomizing 6004 older, AF-naïve persons with risk factors for AF and stroke 1:3 to receive implantable loop recorder screening or usual care. Implantable
-
Right heart catheterization in heart failure: indications, interpretation, and pitfalls Eur. Heart J. (IF 37.6) Pub Date : 2025-06-16 Katarina Zeder, Susanna Mak, Nazzareno Galie, Stephan Rosenkranz, Bradley A Maron
Right heart catheterization (RHC) plays a pivotal role across the spectrum of heart failure, from ambulatory patients to those in cardiogenic shock or under consideration for left ventricular assist device (LVAD) therapy and heart transplantation. Hemodynamic data are critical for early recognition of clinical deterioration, prognostication, and guiding treatment decisions. This state-of-the-art review
-
Championing environmental sustainability in cardiology: the ESC Task Force's vision for a healthier future. A Task Force with a mission. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-16 Thomas Münzel,Massimo Piepoli,Sanjay Rajagopalan,
-
Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a). Eur. Heart J. (IF 37.6) Pub Date : 2025-06-16 Anders B Wulff,Børge G Nordestgaard
-
Plaque erosion, association between periodontal and cardiovascular disease, and obesity-associated cardiovascular ageing. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-16 Filippo Crea
-
A Vienna Symphony of Advances in Arrhythmia Care: insights from the European Heart Rhythm Association 2025. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-15 Natasja M S de Groot,Stylianos Tzeis,Helmut Pürerfellner
-
The European Cardio Summit in Romania. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-14 Ovidiu Chioncel,Thomas F Lüscher
-
Cardio Egypt 2025: report from the Egyptian Society of Cardiology. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-13 Magdy Abdelhamid,Gamela Nasr,Nabil Farag
-
Stakeholder meeting report for ENHANCE CVH: a trial to improve maternal and child cardiovascular health in Nigeria. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Cecilia Naa O Nartey,Mark D Huffman,Dike B Ojji
-
-
The '10 Commandments' from the 2025 ESC/EHRA Clinical Consensus Statement on Indications for Conduction System Pacing (CSP). Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Yoav Michowitz,Michael Glikson,Haran Burri
-
Sammy Basso, his life and message, and the importance of progeria research. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Giovanna Lattanzi
-
Tackling cardiovascular diseases in sub-Saharan Africa: the Africa-Europe CoRE in non-communicable disease and multimorbidity. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Pasquale Maffia,Bamba Gaye,Frederick Bukachi,
-
Innovative artificial intelligence for practice management in medical healthcare. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Dominik Zurek,Roberto Corizzo,Lukasz Koltowski
-
Epidemic of cardio-metabolic disorders in south Asia: need for urgent solutions. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Thyparambil Aravindakshan PramodKumar,Viswanathan Mohan
-
Sudan conflict: impact on interrupted care after acute myocardial infarction. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Ibrahim Nagmeldin Hassan,Hamza Ashraf,Abdulkarim Hasan
-
CardioMetabolic medicine: the advent of systems cardiology and the new cardiovascular generalist? Eur. Heart J. (IF 37.6) Pub Date : 2025-06-12 Thomas F Lüscher
Cardiometabolic medicine is centre stage currently as it integrates organ dysfunction in the pancreas, kidney, liver, and the heart induced by the pandemic of obesity leading to a high risk of heart failure with preserved or reduced ejection fraction, myocardial infarction, stroke, and pre-mature death. This novel specialty requires special, generalized training across several specialties in order
-
Great debate: ablation of atrial fibrillation should be performed in patients with heart failure with reduced ejection fraction. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-10 Cecilia Linde,Milton Packer,Johann Bauersachs
-
Focus on trials: interventional cardiology, ischaemic heart disease, and long COVID. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-09 Filippo Crea
-
-
Great debate: Transcatheter aortic valve implantation should also be performed in non-surgical centres. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-05 Miriam Compagnone,Stephan Windecker,Gianni Dall'Ara,Marcello Galvani,Simone Grotti,Matthias Siepe,Fabio Felice Tarantino,Daijiro Tomii,Marina Urena,Helmut Baumgartner
-
The double-edged sword of heart rate lowering in cardiovascular disease. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-05 Franz H Messerli,Louis Hofstetter,Sripal Bangalore
-
Mastering percutaneous coronary intervention in calcified coronary lesions with optical coherence tomography: the path to optimal outcomes. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-05 Marta Belmonte,Emanuele Barbato
-
Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure Eur. Heart J. (IF 37.6) Pub Date : 2025-06-05 Liangliang Li, Jiayu Guo, Jiayue Feng, Tianyu Li, Bingqian Xu, Wei Li, Na Yang, Weihang Ji, Shuping Zhuang, Yiding Geng, Bin Wang, Jinping Liu, Jian Sun, Yingying Guo, Ruoxuan Yang, Zhiwei Ning, Yan Wang, Qiudi Liu, Xiaomu Tian, Hongli Shan, Baofeng Yang, Haihai Liang
Background and Aims Previous studies have highlighted the significance of RNA-binding proteins and alternative splicing (AS) in the progression of complex diseases, but the specific involvement of AS in heart failure (HF) remains unclear. This study aimed to elucidate the role of RNA-binding motif single-stranded interacting protein 1 (RBMS1), an RNA-binding protein, in the development of HF by regulating
-
Optical coherence tomography- vs angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial Eur. Heart J. (IF 37.6) Pub Date : 2025-06-05 Ziad A Ali, Doosup Shin, Rajesh Vijayvergiya, Atit A Gawalkar, Richard A Shlofmitz, Fernando Alfonso, Giuseppe Calligaris, Paolo Canova, Koshiro Sakai, Matthew J Price, David Leistner, Francesco Prati, Gary Mintz, Mitsuaki Matsumura, Robert J McGreevy, Robert W McNutt, Hong Nie, Jana Buccola, Ulf Landmesser, Akiko Maehara, Gregg W Stone
Background and Aims The large-scale, randomized ILUMIEN IV trial was examined to determine whether procedural guidance with optical coherence tomography (OCT) during percutaneous coronary intervention (PCI) of angiographically calcified lesions improves outcomes. Methods Patients with a single PCI target lesion were included in the present analysis. The presence of none, mild, moderate or severe lesion
-
Ferroptosis in cardiovascular disease: regulatory mechanisms and therapeutic implications Eur. Heart J. (IF 37.6) Pub Date : 2025-06-04 Yiheng Zhao, Andreas Linkermann, Masafumi Takahashi, Qingguo Li, Xiang Zhou
Ferroptosis, an iron-dependent form of regulated cell death, has been identified as a key factor in the pathogenesis and progression of various cardiovascular diseases (CVDs). The molecular basis of ferroptosis involves lipid peroxidation, iron dysregulation, and antioxidant pathways. Accumulating evidence suggests that ferroptosis is associated with various CVDs, including atherosclerosis, myocardial
-
The Construction and Development of China's National Basic Science Center for Panvascular Interventional Complex Systems: Pioneering Device-Vessel Suitcordance Research. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-04 Lingsen You,Li Shen,Junbo Ge
-
High-stakes hypertrophy: implications of elevated sudden cardiac death rates in competitive bodybuilders. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03 James M Smoliga
-
The invisible costs of heart failure: a societal toll. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03 Norrisa Haynes,Erica S Spatz
-
KCNB1: a new player among the suspects of cardiogenetic arrhythmias. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03 Kristina H Haugaa,Ivana Haby
-
Physiological stenosis assessment for coronary artery surgery: quo vadis? Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03 Philippe Kolh,Vincent Tchana-Sato,Thomas A Schwann
-
Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03 Georgia K Chaseling, Izabella Uchmanowicz, Maria Bäck, Òscar Miró, Maryia Tokmakova, Petter Ljungman, Jari Laukkanen, Rosa Maria Bruno, George Ntaios, Bianca Rocca, Ollie Jay, Lacy M Alexander, W Larry Kenney, Philip Moons
Globally, hot weather and heatwaves are claiming lives and are predicted to become increasingly deadly under all future climate change scenarios. Rising global temperatures pose a significant risk on cardiovascular health, disproportionately impacting the elderly and people with cardiovascular disease (CVD). However, despite convincing epidemiological data demonstrating this increased cardiovascular
-
New pieces to the jigsaw of antiplatelet treatment after acute coronary syndrome, and a focus on leadless pacing. Eur. Heart J. (IF 37.6) Pub Date : 2025-06-02 Filippo Crea
-
Zoster vaccination for cardiovascular disease prevention? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30 Christian Torp-Pedersen,Tor Biering Sørensen
-
Unravelling heart failure cellular signalling heterogeneity with spatial transcriptomics. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30 Simon Tual-Chalot,Konstantinos Stellos
-
Heart failure: assessment of the global economic burden Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30 Mohammad Darvish, Abdul Shakoor, Lida Feyz, Jeroen Schaap, Nicolas M van Mieghem, Rudolf A de Boer, Jasper J Brugts, Robert M A van der Boon
Background and Aims Heart failure (HF) is a major public health issue, imposing substantial costs on healthcare systems and societies. This study aimed to provide a contemporary overview of its global economic impact. Methods A systematic search of four databases was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies reporting direct cost
-
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30 William A E Parker, Thomas A Nelson, Justin Lee, Heather M Judge, Ramzi A Ajjan, Johan Westerbergh, Agneta Siegbahn, Christina Christersson, John H Alexander, Renato D Lopes, Christopher B Granger, Elaine M Hylek, Lars Wallentin, Robert F Storey
Background and Aims Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction
-
Data sharing statements: impact of journal policies across clinical research disciplines Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30 Daniel Archer, Noah Barks, Mahad Chaudhry, Brody Dennis, Jacob Duncan, Annes Elfar, Taylor Gardner, Eli Paul, Micah Kee, Alicia Ito Ford, Matt Vassar
Background and Aims Cardiovascular disease is a leading cause of mortality, with significant investments in research to improve treatment and prevention. Data sharing enhances transparency, reproducibility, and collaboration, yet data sharing statement (DSS) inclusion remains inconsistent. This study evaluates DSS prevalence, content, and influencing factors in high-impact cardiology journals, examines
-
Preventive stenting of vulnerable plaques in diabetic patients: is it worth it? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29 Diana A Gorog
-
Rising demand vs limited access: should cardiologists perform mechanical thrombectomy? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29 Peter Lanzer
-
Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29 Min Chul Kim, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Do-Yoon Kang, Won-Jang Kim, Chang-Wook Nam, Jin-Ok Jeong, In-Ho Chae, Hiroki Shiomi, Hsien-Li Kao, Joo-Yong Hahn, Sung-Ho Her, Bong-Ki Lee, Tae Hoon Ahn, Kiyuk Chang, Jei Keon Chae, David Smyth, Gary S Mintz, Gregg W Stone, Youngkeun Ahn
Background and Aims The efficacy and safety of preventive percutaneous coronary intervention (PCI) for treating vulnerable plaques in diabetic patients remain unclear. Methods The PREVENT (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) trial was a randomized clinical trial that compared preventive PCI plus optimal medical therapy with optimal medical
-
Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29 K Lance Gould, Nils P Johnson, Amanda E Roby, Richard Kirkeeide, Mary Haynie, Tung Nguyen, Linh Bui, Monica B Patel, Danai Kitkungvan, Patricia Mendoza, Dejian Lai, Ruosha Li, Stefano Sdringola, David McPherson, Jagat Narula
Background and Aims The randomized CENTURY trial tested the hypothesis that a comprehensive strategy integrating intense lifestyle modification and aggressive medical management to goals with revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET) would reduce risk factors, subsequent revascularization, death and myocardial infarction (MI)
-
Statins beat device-related in-stent neo-atherosclerosis: pathophysiology reigns supreme. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-27 William Wijns,Shengxian Tu
-
Weekly Journal Scan: Extending anticoagulation beyond 6 months after venous thromboembolism in patients with active cancer. Is low-dose apixaban the answer? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-27 Mattia Galli,Carlo Patrono
-
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-26 Mario Berger,Aidan MacNamara,João Pedro Ferreira,Peter Kolkhof,Sebastian Voss,Adam Skubala,Andrea Scalise,Laura Goea,Richard Nkulikiyinka,Bertram Pitt,Joachim Hanno Ix,Peter Rossing,Richard John Mark Coward,Faiez Zannad,Hiddo J L Heerspink
-
An update on the Council for Cardiology Practice of the European Society of Cardiology. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-26 Luigina Guasti,Konstantinos Toutouzas,Ruxandra Christodorescu
-
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22 Niki Procopi, Michel Zeitouni, Mathieu Kerneis, Guillaume Cayla, Emile Ferrari, Grégoire Range, Etienne Puymirat, Nicolas Delarche, Paul Guedeney, Farzin Beygui, Laurent Desprets, Jean-Louis Georges, Thomas Bochaton, François Schiele, Grégory Ducrocq, Marie Hauguel-Moreau, Raphaelle Dumaine, Michel S Slama, Laurent Payot, Mohamad El Kasty, Karim Aacha, Abdourahmane Diallo, Xavier Girerd, Eric Vicaut
Background and Aims This study aims to report the effects of β-blocker interruption on blood pressure (BP) and heart rate (HR) in the AβYSS trial where patients were randomized to interruption or continuation of β-blocker treatment after a myocardial infarction (MI). Methods Changes in HR and BP from baseline to post-randomization are reported using linear mixed repeated model, in the 3698 patients
-
Staring into the AβYSS: how many pills and for how long after myocardial infarction? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22 John G F Cleland
-
Posterior left pericardiotomy in cardiac surgery and outcomes: PALACS-EF trial extended follow-up. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22 Mario Gaudino,Lamia Harik,Bjorn Redfors,Jordan Leith,Alexander C Gregg,Jessica Kim,Rachel Heise,Lisa Q Rong,Sigrid Sandner,Antonino Di Franco,Charles A Mack,Christopher Lau,Tommaso Sanna,Giovanni J Soletti,Jonathan W Weinsaft,Gianni D Angelini,John H Alexander,Leonard N Girardi
-
Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22 Harold Mathijssen, Parag H Bawaskar, Yogita Rochlani, Issac Georgy, Pal Satyajit Singh Athwal, Yugene Guo, Daniel Pollmann, Jeremy Markowitz, Lisa Von Wald, Henri Roukoz, David Perlman, Maneesh Bhargava, Leandro Slipczuk, Annalisa Filtz, Julio Andres Ovalle Ramos, Saurabhi Samant, Sanya Chhikara, Francesco Castagna, Marcel Veltkamp, Fatima Akdim, Annelies L M Bakker, Marco C Post, Chetan Shenoy
Background and Aims Implementing societal recommendations for primary prevention implantable cardioverter-defibrillators (ICDs) in cardiac sarcoidosis requires an accurate diagnosis. However, cardiac sarcoidosis diagnostic schemes are inconsistent and often produce conflicting results. This study aimed to compare the discriminative accuracy of cardiovascular magnetic resonance imaging (CMR) phenotyping
-
New level of evidence grading system for Guidelines, artificial intelligence, and adult congenital heart disease. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Filippo Crea
-
Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases–nuclear factor κB pathway in cardiomyocytes Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Mengyang Wang, Xue Han, Qinyan Wang, Tianxiang Yu, Wu Luo, Shiju Ye, Xiaochen Guo, Zheng Xu, Zhuqi Huang, Julian Min, Ping Huang, Yi Wang, Guang Liang
Background and Aims Hypertensive heart failure has an urgent need for new therapeutic targets. Protein kinases act as key regulators in cellular actions relevant to cardiac pathophysiology. This study identified a protein kinase, Wee1 G2 checkpoint kinase (Wee1), being activated and involved in this disease. Methods RNA-seq-based kinase enrichment analysis was used to identify the involved kinase pathways
-
Weekly Journal Scan: The five-year follow-up of FAME 3 keeps open the never-ending debate about coronary artery bypass grafting vs percutaneous coronary intervention in patients with three-vessel disease. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Antonio Maria Leone,Rocco Vergallo
-
Catheter ablation in congenital heart diseases: a French nationwide study Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Victor Waldmann, Guillaume Duthoit, Jean-Luc Pasquié, Laure Champ-Rigot, Mathieu Albertini, Frédéric Anselme, Stefano Bartoletti, Damien Bonnet, Charlène Bredy, Sok-Sithikun Bun, Gaël Clerici, Antoine Da Costa, Christian De Chillou, Pascal Defaye, Maxime de Guillebon, Clément Davril, Antoine Delinière, Nicolas Derval, Geoffroy Ditac, Kevin Gardey, Caroline Ghanimé, Jean-Baptiste Gourraud, Sébastien
Background and Aims Current evidence on catheter ablation for patients with congenital heart disease (CHD) is derived from small, retrospective studies. This study aims to provide insights from a nationwide contemporary registry. Methods This prospective study included all CHD patients referred for catheter ablation from 2020 to July 2024 across 28 French centres. The primary outcome was the rate of
-
Twin pregnancies: impact of infertility treatments and postpartum lifestyle on maternal heart health. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Ruby Lin,Cande V Ananth
-
Key points for analysing cardiovascular disease after delivery of twin pregnancies. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Xin Li,Xue Xiao,Tianjiao Liu
-
A 14.6 cm paediatric aortic monster: first LOX mutation shattering size records in childhood thoracic aortic aneurysm and dissection. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Nanjun Zhang,Jianfeng Pu,Chuan Wang
-
Family history of aortic dissection in fibrillin-1 pathogenic variant. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Maria Tchitchinadze,Olivier Milleron,Ludivine Eliahou,Sabrine Jadoui,Nadia Ould Ouali,Nadine Hanna,Pauline Arnaud,Jacques Ropers,Catherine Boileau,Laurent Gouya,Guillaume Jondeau
-
Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21 Tomas Baka, Jarrod Moore, Fuzhong Qin, Salva R Yurista, Aifeng Zhang, Huamei He, Jordan M Chambers, Dominique Croteau, Raghuveera K Goel, Hunter Smith, Miranda C Wang, Christopher S Chen, Ion A Hobai, Martina Rombaldova, Ondrej Kuda, Jil C Tardiff, James A Balschi, David R Pimentel, Christine E Seidman, Jonathan G Seidman, Andrew Emili, Wilson S Colucci, Ivan Luptak
Background and Aims Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, and impaired metabolic efficiency. This study investigates the therapeutic potential of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin (EMPA) in ameliorating these pathological features in a mouse model carrying the myosin